Abstract
Activation enhanced cell death (AECD) involves stimulating cells with growth or activation signals while concurrently blocking calcium influx. In this study, we have evaluated the effect of AECD on human breast cancer cells. MCF-7 or MDA-MB-231 cells treated with Ca2+ influx blockers econazole or ketotifen for 24 h underwent a dose-dependent, irreversible loss of viability, and clonogenicity. Two-hour treatment of these cells with higher concentrations of the drugs also resulted in loss of clonogenicity, but morphological indicators of cell death were apparent only after longer incubation. Loss of clonogenicity could be enhanced almost 10-fold by co-stimulation of the cells with the agonists EGF or bombesin. Econazole was also effective in inducing cell death in multi-drug resistant MCF-7adr cells. Human hemopoietic progenitor cell sensitivity to econazole or ketotifen was evaluated by colony assay. Under conditions resulting in 2.5–3 logs of breast cancer cell loss, 60–70% of hemopoietic progenitors could be recovered. We further evaluated the effect of econazole on breast cancer cells present in mobilized hemopoietic cells obtained from patients undergoing high dose chemotherapy with autologous stem cell support. In six of eight samples evaluated, cytokeratin-positive breast cancer cells could be detected by immunofluorescence microscopy and colony formation. Breast cancer colonies were reduced 60–500-fold or more after exposure to econazole while hemopoietic colonies were typically reduced only 2-fold. In all cases, addition of EGF as an activator either had no evaluable effect or enhanced breast cancer cell loss. We conclude that Ca2+ influx blockade with concurrent EGF stimulation is a promising approach for purging breast cancer cells from hemopoietic progenitor cell preparations.
Similar content being viewed by others
References
Peters WP: High Dose Chemotherapy with Autologous Bone Marrow Transplantation for the Treatment of Breast Cancer. Philadelphia, Lippincott, 1995
Peters WPJ, Vredenburgh RB, Shpall J, Hussein EJ, Elkordy A, Rubin M, Ross P, Berry M, D: A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proceedings of ASCO, 121, 1996
Lotz JP, Cure H, Janvier M, Morvan F, Legros M, Asselain B, Guillemot M, Roche H, Gisselbrecht C: Intensive chemotherapy and autograft of hematopoietic stem cells in the treatment of metastatic cancer: results of the national protocol Pegase 04. Hematol Cell Ther 41: 71–74, 1999
Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH: Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 342: 1069–1076, 2000
Peters WP, Dansey RD, Klein JL, Baynes RD: High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist 5: 1–13, 2000
Rodenhuis S: The status of high-dose chemotherapy in breast cancer. Oncologist 5: 369–375, 2000
Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Akard L, Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG, Warner NE: Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 82: 2605–2610, 1993
Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, Roth MS: Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 12: 475–482, 1994
Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L: Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 83: 636–640, 1994
Spyridonidis A, Bernhardt W, Fetscher S, Behringer D, Mertelsmann R, Henschler R: Minimal residual disease in autologous hematopoietic harvests from breast cancer patients. Ann Oncol 9: 821–826, 1998
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J, Jr, Anderson WF, Ihle JN: Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341: 85–86, 1993
Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK: Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84: 380–383, 1994
Freedman A, Friedberg JW, Gribben J: High-dose therapy for follicular lymphoma. Oncology (Huntingt) 14: 321–326, 329; discussion 330–332, 338, 2000
Shpall EJ, Jones RB, Bast RC, Jr, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M, Coniglio D, Peters WP: 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol 9: 85–93, 1991
Anderson IC, Shpall EJ, Leslie DS, Nustad K, Ugelstad J, Peters WP, Bast RC, Jr: Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 49: 4659–4664, 1989
Passos-Coelho J, Ross AA, Davis JM, Huelskamp AM, Clarke B, Noga SJ, Davidson NE, Kennedy MJ: Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect of ex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res 54: 2366–2371, 1994
Fauth F, Martin H, Sonnhoff S, Bialleck H, Wiesneth M, Mihanovic B, Hoelzer D: Purging of G-CSF-mobilized peripheral autografts in acute leukemia with mafosfamide and amifostine to protect normal progenitor cells. Bone Marrow Transplant 25: 831–836, 2000
Shpall EJ, Jones RB, Bearman SI, Franklin WA, Archer PG, Curiel T, Bitter M, Claman HN, Stemmer SM, Purdy M, Myers SE, Hami L, Taffs S, Heimfeld S, Hallagan J, Berenson RJ: Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol 12: 28–36, 1994
Chabannon C, Cornetta K, Lotz JP, Rosenfeld C, Shlomchik M, Yanovitch S, Marolleau JP, Sledge G, Novakovitch G, Srour EF, Burtness B, Camerlo J, Gravis G, Lee-Fischer J, Faucher C, Chabbert I, Krause D, Maraninchi D, Mills B, Kunkel L, Oldham F, Blaise D, Viens P: High-dose chemotherapy followed by reinfusion of selected CD34+ peripheral blood cells in patients with poor-prognosis breast cancer: a randomized multicentre study. Br J Cancer 78: 913–921, 1998
Kennedy MJ: Peripheral blood progenitor cell mobilization: a clinical review. Pharmacotherapy 18: 3S–8S, 1998
Gommerman JL, Berger SA: Protection from apoptosis by steel factor but not interleukin-3 is reversed through blockade of calcium influx. Blood 91: 1891–1900, 1998
Fox SB, Smith K, Hollyer J, Greenall M, Hastrich D, Harris AL: The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. Breast Cancer Res Treat 29: 41–49, 1994
Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 4: 19–26, 1993
Peyrat JP, Bonneterre J, Hondermarck H, Hecquet B, Adenis A, Louchez MM, Lefebvre J, Boilly B, Demaille A: Basic fibroblast growth factor (bFGF): mitogenic activity and binding sites in human breast cancer. J Steroid Biochem Mol Biol 43: 87–94, 1992
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989
el Yazidi I, Boilly-Marer Y: Production of acidic and basic fibroblast growth factor by the hormone-independent breast cancer cell line MDA-MB-231. Anticancer Res 15: 783–790, 1995
Mossman T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Immunol Meth 65: 55, 1983
Bian X, Hughes FM, Jr, Huang Y, Cidlowski JA, Putney JW, Jr: Roles of cytoplasmic Ca2+ and intracellular Ca2+ stores in induction and suppression of apoptosis in S49 cells. Am J Physiol 272: C1241–1249, 1997
Putney JW, Jr, McKay RR: Capacitative calcium entry channels. Bioessays 21: 38–46, 1999
Kueng WM, Silber E, Novak I, Eppenberger U: Effects of hormones and growth factors on the growth of six human breast cancer cell lines in defined media. Contribut Oncol 23: 26–32, 1986
Dong XF, Berthois Y, Martin PM: Effect of epidermal growth factor on the proliferation of human epithelial cancer cell lines: correlation with the level of occupied EGF receptor. Anticancer Res 11: 737–743, 1991
Bold RJ, Ishizuka J, Yao CZ, Townsend CM, Jr, Thompson JC: Bombesin stimulates in vitro growth of human breast cancer independent of estrogen receptors status. Anticancer Res 18: 4051–4056, 1998
Yano T, Pinski J, Groot K, Schally AV: Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines. Cancer Res 52: 4545–4547, 1992
Gottesman MM, Pastan I: Biochemistry of multi-drug resistance mediated by the multi-drug transporter. Annu Rev Biochem 62: 385–427, 1993
Lehnert M: Clinical multi-drug resistance in cancer: a multifactorial problem. Eur J Cancer 32A: 912–920, 1996
Gamberucci A, Fulceri R, Benedetti A, Bygrave FL: On the mechanism of action of econazole, the capacitative calcium inflow blocker. Biochem Biophys Res Commun 248: 75–77, 1998
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhang, Y., Crump, M. & Berger, S.A. Purging of Contaminating Breast Cancer Cells From Hematopoietic Progenitor Cell Preparations Using Activation Enhanced Cell Death. Breast Cancer Res Treat 72, 265–278 (2002). https://doi.org/10.1023/A:1014965726663
Issue Date:
DOI: https://doi.org/10.1023/A:1014965726663